Not provided
Not provided
Not provided
Not provided
Not provided
difficulty recruiting patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The mortality rate is increased in patients with epilepsy, and especially among patients with drug-resistant epilepsy. This increased mortality is mainly related to the risk of SUDEP whose incidence is between 3.5 and 9 per 1,000 for patients with drug-resistant epilepsy. The term SUDEP refers to a sudden death occurring in a patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause. Experimental and clinical data strongly suggest that most of SUDEP result from a postictal respiratory dysfunction progressing to terminal apnea. Due to the major role of serotonin in regulating breathing rhythms and data in animal models of epilepsy, it is envisaged that an alteration of serotonergic systems of the brainstem and limbic regions may play a central role in the occurrence of SUDEP. The objective of this work is to look for abnormalities of the serotonergic transmission within regulatory regions of respiratory and autonomic functions in brain samples prospectively collected in patients died from SUDEP.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| diagnostic of SUDEP | patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected. |
| |
| Control 1 | Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected. |
| |
| Control 2 | Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brain samples | Other | Collected in patients died |
|
| Measure | Description | Time Frame |
|---|---|---|
| Density of Medullary 5-HT Neurons | 5-HT1A receptor binding density in within the medulla | between 1 to 30 hours following death |
| Measure | Description | Time Frame |
|---|---|---|
| Other markers of 5HT within the medulla | Expression of 5HT-1A and 5HT-2 receptors, expression of 5HT transporter, Tryptophan Hydroxylase 2 (TPH2) | between 1 to 30 hours following death |
| Serotoninergic pathway in the pons, the hippocampus and the insula |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with epilepsy who died
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon - Institut Médico-Légal | Lyon | 69008 | France |
Not provided
| ID | Term |
|---|---|
| D000080485 | Sudden Unexpected Death in Epilepsy |
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D003645 | Death, Sudden |
Not provided
Not provided
Not provided
Not provided
Not provided
Brain tissue (brainstem, hippocampus and insula) and fibroblasts culture
| Skin samples | Other | Collected in patients died |
|
5-HT1A receptor binding density, Expression of 5HT-1A and 5HT-2 receptors, expression of 5HT transporter, Tryptophan Hydroxylase 2 (TPH2) |
| between 1 to 30 hours following death |
| Catecholaminergic pathway | Number of neurons expressing the tyrosine hydroxylase, expression of alpha and beta adrenergic receptors, expression of dopamine-bêta-hydroxylase | between 1 to 30 hours following death |
| D003643 |
| Death |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |